How a Triple-Hormone Medication Works, What Early Trial Results Actually Show, and Who Should Consider It Over Semaglutide or Tirzepatide — A Physician’s Guide for Des Plaines, Park Ridge, Niles, and the Northwest Suburbs
By Dr. Naaz Aziz, MD, Board-Certified Family Medicine Physician · Zorah Med Spa, Des Plaines, IL · Updated September 2026
Zorah Med Spa — 1645 S River Road, Suite 14, Des Plaines, IL 60018, River Plaza Professional Building, off River Road near the Rosemont border, serving Des Plaines, Park Ridge, Niles, and surrounding suburbs. Six days a week, 9 to 5, Monday through Saturday. (708) 412-4040 · schedule a consultation online.
Quick answer: Retatrutide is the newest weight loss medication available, and what sets it apart is that it activates three hormone receptors instead of one or two — GLP-1, GIP, and glucagon. Semaglutide activates only GLP-1; tirzepatide activates GLP-1 and GIP. That third pathway, glucagon receptor activation, is believed to contribute to retatrutide’s notably strong results in early trials, which have shown greater average weight loss than either of the other two medications. It’s not automatically the right choice for everyone, but it’s worth understanding if you’re evaluating your options.
How Retatrutide Actually Works
Like semaglutide and tirzepatide, retatrutide is a synthetic hormone analog that mimics natural signals involved in appetite regulation and metabolism. GLP-1 activation slows digestion and signals fullness to the brain. GIP activation, shared with tirzepatide, appears to enhance the effect on blood sugar regulation and may contribute to additional weight loss benefit. The addition of glucagon receptor activation is what’s unique to retatrutide — glucagon plays a role in energy expenditure and fat metabolism, and activating this third pathway is believed to be part of why retatrutide has shown such notable results in trials so far.
What Early Trial Data Actually Shows
Retatrutide is newer than semaglutide and tirzepatide, meaning its trial data, while promising, spans a shorter track record than the other two medications. Early trial results have shown average weight loss exceeding what’s been reported for semaglutide and, in some trials, exceeding tirzepatide as well, at the highest doses studied. This has generated significant interest in retatrutide as a potentially more effective option for patients who haven’t achieved their goals on other GLP-1 medications, though as with any newer medication, more real-world, long-term data continues to accumulate.
How Dosing Works
Like the other GLP-1 medications, retatrutide follows a gradual dose escalation, starting low and increasing in steps over the following weeks and months to allow your body to adjust and to minimize gastrointestinal side effects. This slow, monitored approach is standard across all medications in this category and is not unique to retatrutide, but it’s worth understanding that starting on retatrutide doesn’t mean starting at a high dose immediately.
Who Might Consider Retatrutide
Patients who’ve plateaued on semaglutide or tirzepatide, patients with a higher amount of weight to lose who may benefit from a medication with a stronger average effect in trials, and patients starting treatment for the first time who want to discuss every available option before choosing a starting point are all reasonable candidates for a conversation about retatrutide. It is not automatically the right first choice for every new patient — this is a decision made individually based on your health history, goals, and physician evaluation.
Side Effects: What to Expect
Retatrutide’s side effect profile is broadly similar to other GLP-1 medications — nausea, digestive discomfort, and fatigue are most common, particularly during dose increases, and tend to improve as your body adjusts to each step. Because it activates an additional hormone pathway compared to semaglutide, ongoing monitoring for any distinct patterns in side effects is part of routine follow-up care while data on the medication continues to mature.
How This Fits Into a Membership Plan
Retatrutide is available for patients whose evaluation supports it as an appropriate choice, and can be incorporated into a broader weight loss membership plan alongside the metabolic and muscle-preservation support offered through our other membership components. Whether retatrutide, semaglutide, or tirzepatide fits your specific membership tier and goals is determined at your consultation.
Retatrutide vs. Semaglutide vs. Tirzepatide: The Short Version
Semaglutide activates one hormone pathway and has the longest track record. Tirzepatide activates two and has shown stronger average results than semaglutide in head-to-head comparisons. Retatrutide activates three and has shown the strongest average results in early trials among the three, though with a shorter overall track record than the other two. More pathways activated doesn’t automatically mean the right choice for every patient — the right starting point depends on your history, prior response to treatment, and physician evaluation.
Frequently Asked Questions
Is retatrutide FDA-approved?
Availability and approval status for weight management continue to evolve as data matures; your physician can explain the current regulatory status at your consultation.
Is retatrutide stronger than tirzepatide?
Early trial data has shown greater average weight loss with retatrutide at studied doses, though individual response varies and tirzepatide remains highly effective for many patients.
Should I start with retatrutide instead of semaglutide?
Not necessarily. Many patients still appropriately start with semaglutide or tirzepatide; retatrutide is one option among several, and the right starting point depends on your individual evaluation.
What are the most common side effects?
Nausea, digestive discomfort, and fatigue, particularly during dose increases — similar to other GLP-1 medications, and typically improving as the body adjusts.
Can I switch from tirzepatide to retatrutide if I’ve plateaued?
This is a reasonable conversation to have with your physician, who can evaluate whether switching makes sense based on your specific response and history.
Where are you, and how do I book a consultation?
1645 S River Road, Suite 14, Des Plaines, IL 60018, open 9 to 5, six days a week. Book onlineor call; new patients are welcome.
Discuss Every Option Before You Start
Retatrutide, semaglutide, and tirzepatide each work differently, and the right choice depends on your specific situation. Schedule a consultation with Dr. Aziz or call (708) 412-4040. Still have questions? Check our Med Spa FAQ or reach out directly.
Zorah Med Spa · 1645 S River Road, Suite 14, Des Plaines, IL 60018 · (708) 412-4040 · Monday–Saturday, 9 AM–5 PM
Individual results vary and are not guaranteed. This guide is educational and reflects available trial data as of publication; your specific treatment plan is determined by a licensed physician after a consultation and evaluation.
